Published in Nat Rev Cancer on June 01, 2013
Sialic acid metabolic engineering: a potential strategy for the neuroblastoma therapy. PLoS One (2014) 1.45
Sparstolonin B, a novel plant derived compound, arrests cell cycle and induces apoptosis in N-myc amplified and N-myc nonamplified neuroblastoma cells. PLoS One (2014) 1.44
ALK mutations confer differential oncogenic activation and sensitivity to ALK inhibition therapy in neuroblastoma. Cancer Cell (2014) 1.36
Inactivation of SMC2 shows a synergistic lethal response in MYCN-amplified neuroblastoma cells. Cell Cycle (2014) 1.05
Pediatric solid tumor genomics and developmental pliancy. Oncogene (2015) 1.00
DriverDB: an exome sequencing database for cancer driver gene identification. Nucleic Acids Res (2013) 0.99
A role for TRAIL/TRAIL-R2 in radiation-induced apoptosis and radiation-induced bystander response of human neural stem cells. Apoptosis (2014) 0.95
Common genetic variants in NEFL influence gene expression and neuroblastoma risk. Cancer Res (2014) 0.94
CASC15-S Is a Tumor Suppressor lncRNA at the 6p22 Neuroblastoma Susceptibility Locus. Cancer Res (2015) 0.89
Glycobiology of neuroblastoma: impact on tumor behavior, prognosis, and therapeutic strategies. Front Oncol (2014) 0.88
The P2X7 receptor is a key modulator of the PI3K/GSK3β/VEGF signaling network: evidence in experimental neuroblastoma. Oncogene (2015) 0.87
Candidate Gene Association Analysis of Neuroblastoma in Chinese Children Strengthens the Role of LMO1. PLoS One (2015) 0.86
Multidrug resistance and cancer stem cells in neuroblastoma and hepatoblastoma. Int J Mol Sci (2013) 0.86
Structural design of disialoganglioside GD2 and CD3-bispecific antibodies to redirect T cells for tumor therapy. Int J Cancer (2014) 0.86
Energy metabolism in neuroblastoma and Wilms tumor. Transl Pediatr (2015) 0.86
Metformin impairs Rho GTPase signaling to induce apoptosis in neuroblastoma cells and inhibits growth of tumors in the xenograft mouse model of neuroblastoma. Oncotarget (2014) 0.85
MYCN amplified neuroblastoma requires the mRNA translation regulator eEF2 kinase to adapt to nutrient deprivation. Cell Death Differ (2017) 0.85
N-Myc differentially regulates expression of MXI1 isoforms in neuroblastoma. Neoplasia (2013) 0.85
Imaging the norepinephrine transporter in neuroblastoma: a comparison of [18F]-MFBG and 123I-MIBG. Clin Cancer Res (2014) 0.85
Epigenetic therapy of cancer stem and progenitor cells by targeting DNA methylation machineries. World J Stem Cells (2015) 0.85
Retargeting T cells to GD2 pentasaccharide on human tumors using Bispecific humanized antibody. Cancer Immunol Res (2014) 0.84
Translational compensation of genomic instability in neuroblastoma. Sci Rep (2015) 0.84
Novel ALK inhibitor AZD3463 inhibits neuroblastoma growth by overcoming crizotinib resistance and inducing apoptosis. Sci Rep (2016) 0.83
Phosphatidylinositol 3-kinase, class 2 beta (PI3KC2β) isoform contributes to neuroblastoma tumorigenesis. Cancer Lett (2015) 0.83
Wild-type ALK and activating ALK-R1275Q and ALK-F1174L mutations upregulate Myc and initiate tumor formation in murine neural crest progenitor cells. Oncotarget (2014) 0.83
Affinity maturation of T-cell receptor-like antibodies for Wilms tumor 1 peptide greatly enhances therapeutic potential. Leukemia (2015) 0.82
The Childhood Solid Tumor Network: A new resource for the developmental biology and oncology research communities. Dev Biol (2015) 0.82
Sensitivity to cdk1-inhibition is modulated by p53 status in preclinical models of embryonal tumors. Oncotarget (2015) 0.82
Feeder-free derivation of neural crest progenitor cells from human pluripotent stem cells. J Vis Exp (2014) 0.82
Intratumoral diversity of telomere length in individual neuroblastoma tumors. Oncotarget (2015) 0.82
NK Cells, Tumor Cell Transition, and Tumor Progression in Solid Malignancies: New Hints for NK-Based Immunotherapy? J Immunol Res (2016) 0.81
Functional interplay between MYCN, NCYM, and OCT4 promotes aggressiveness of human neuroblastomas. Cancer Sci (2015) 0.81
Tumor-infiltrating T lymphocytes improve clinical outcome of therapy-resistant neuroblastoma. Oncoimmunology (2015) 0.81
An unexpected role for caspase-2 in neuroblastoma. Cell Death Dis (2014) 0.81
Cordycepin induces apoptosis and autophagy in human neuroblastoma SK-N-SH and BE(2)-M17 cells. Oncol Lett (2015) 0.81
HMGB1-induced autophagy in Schwann cells promotes neuroblastoma proliferation. Int J Clin Exp Pathol (2015) 0.81
PleiotRHOpic: Rho pathways are essential for all stages of Neural Crest development. Small GTPases (2014) 0.81
JARID1B Expression Plays a Critical Role in Chemoresistance and Stem Cell-Like Phenotype of Neuroblastoma Cells. PLoS One (2015) 0.80
A distinct gene expression signature characterizes human neuroblastoma cancer stem cells. Stem Cell Res (2015) 0.80
High-resolution array CGH profiling identifies Na/K transporting ATPase interacting 2 (NKAIN2) as a predisposing candidate gene in neuroblastoma. PLoS One (2013) 0.80
Integrative DNA methylome analysis of pan-cancer biomarkers in cancer discordant monozygotic twin-pairs. Clin Epigenetics (2016) 0.80
Development and characterization of a human orthotopic neuroblastoma xenograft. Dev Biol (2015) 0.80
TRPM7 maintains progenitor-like features of neuroblastoma cells: implications for metastasis formation. Oncotarget (2015) 0.80
Novel multiple tyrosine kinase inhibitor ponatinib inhibits bFGF-activated signaling in neuroblastoma cells and suppresses neuroblastoma growth in vivo. Oncotarget (2016) 0.80
Alteration of Electrostatic Surface Potential Enhances Affinity and Tumor Killing Properties of Anti-ganglioside GD2 Monoclonal Antibody hu3F8. J Biol Chem (2015) 0.80
Preclinical Models Provide Scientific Justification and Translational Relevance for Moving Novel Therapeutics into Clinical Trials for Pediatric Cancer. Cancer Res (2015) 0.79
Essential role of GATA3 in regulation of differentiation and cell proliferation in SK-N-SH neuroblastoma cells. Mol Med Rep (2014) 0.79
Neuroblastoma patient-derived orthotopic xenografts retain metastatic patterns and geno- and phenotypes of patient tumours. Int J Cancer (2014) 0.79
Neuroblastoma in dialog with its stroma: NTRK1 is a regulator of cellular cross-talk with Schwann cells. Oncotarget (2014) 0.79
Expression of Wilms tumor gene in high risk neuroblastoma: complementary marker to tyrosine hydroxylase for detection of minimal residual disease. Transl Pediatr (2015) 0.79
Prolonged progression-free survival after consolidating second or later remissions of neuroblastoma with Anti-GD2 immunotherapy and isotretinoin: a prospective Phase II study. Oncoimmunology (2015) 0.79
Combating autophagy is a strategy to increase cytotoxic effects of novel ALK inhibitor entrectinib in neuroblastoma cells. Oncotarget (2016) 0.79
Inhibition of CDK4/6 as a novel therapeutic option for neuroblastoma. Cancer Cell Int (2015) 0.78
Co-expression analysis identifies long noncoding RNA SNHG1 as a novel predictor for event-free survival in neuroblastoma. Oncotarget (2016) 0.78
Cinacalcet inhibits neuroblastoma tumor growth and upregulates cancer-testis antigens. Oncotarget (2016) 0.78
γ-Secretase inhibitor I inhibits neuroblastoma cells, with NOTCH and the proteasome among its targets. Oncotarget (2016) 0.78
Involvement of AMP-activated protein kinase in mediating pyrrolo-1,5-benzoxazepine-induced apoptosis in neuroblastoma cells. Invest New Drugs (2016) 0.78
NGF FLIPs TrkA onto the death TRAIL in neuroblastoma cells. Cell Death Dis (2016) 0.78
PD-L1 expression in metastatic neuroblastoma as an additional mechanism for limiting immune surveillance. Oncoimmunology (2015) 0.77
A cell-based high-throughput screen addressing 3'UTR-dependent regulation of the MYCN gene. Mol Biotechnol (2014) 0.77
Etoposide-loaded immunoliposomes as active targeting agents for GD2-positive malignancies. Cancer Biol Ther (2014) 0.77
Glutathione-mediated antioxidant response and aerobic metabolism: two crucial factors involved in determining the multi-drug resistance of high-risk neuroblastoma. Oncotarget (2016) 0.77
Triptolide inhibits cell proliferation and tumorigenicity of human neuroblastoma cells. Mol Med Rep (2014) 0.76
Structural Basis of GD2 Ganglioside and Mimetic Peptide Recognition by 14G2a Antibody. Mol Cell Proteomics (2015) 0.76
Ataxia-telangiectasia mutated (ATM) silencing promotes neuroblastoma progression through a MYCN independent mechanism. Oncotarget (2015) 0.76
Frizzled2 signaling regulates growth of high-risk neuroblastomas by interfering with β-catenin-dependent and β-catenin-independent signaling pathways. Oncotarget (2016) 0.76
MEG3, HCN3 and linc01105 influence the proliferation and apoptosis of neuroblastoma cells via the HIF-1α and p53 pathways. Sci Rep (2016) 0.76
More than the genes, the tumor microenvironment in neuroblastoma. Cancer Lett (2015) 0.76
Phosphoproteomics reveals ALK promote cell progress via RAS/ JNK pathway in neuroblastoma. Oncotarget (2016) 0.76
Assessment of the chemosensitizing activity of TAT-RasGAP317-326 in childhood cancers. PLoS One (2015) 0.76
The impact of S6K1 kinase on neuroblastoma cell proliferation is independent of GLI1 signaling. BMC Cancer (2014) 0.76
Microenvironmental Modulation of Decorin and Lumican in Temozolomide-Resistant Glioblastoma and Neuroblastoma Cancer Stem-Like Cells. PLoS One (2015) 0.76
'Cut from the same cloth': Shared microsatellite variants among cancers link to ectodermal tissues-neural tube and crest cells. Oncotarget (2015) 0.76
TrkB/BDNF signalling patterns the sympathetic nervous system. Nat Commun (2015) 0.76
Effect of sulfasalazine on human neuroblastoma: analysis of sepiapterin reductase (SPR) as a new therapeutic target. BMC Cancer (2015) 0.76
Novel Platinum(II) compounds modulate insulin-degrading enzyme activity and induce cell death in neuroblastoma cells. J Biol Inorg Chem (2014) 0.76
Regulation of Differentiation by Calcium-Sensing Receptor in Normal and Tumoral Developing Nervous System. Front Physiol (2016) 0.76
Prospect of Human Pluripotent Stem Cell-Derived Neural Crest Stem Cells in Clinical Application. Stem Cells Int (2016) 0.75
MYCN-targeting vaccines and immunotherapeutics. Hum Vaccin Immunother (2016) 0.75
Genome-wide microarray expression and genomic alterations by array-CGH analysis in neuroblastoma stem-like cells. PLoS One (2014) 0.75
Anti-ALK Antibodies in Patients with ALK-Positive Malignancies Not Expressing NPM-ALK. J Cancer (2016) 0.75
Expression of FOXP3, CD14, and ARG1 in Neuroblastoma Tumor Tissue from High-Risk Patients Predicts Event-Free and Overall Survival. Biomed Res Int (2015) 0.75
Functional role of ALK-related signal cascades on modulation of epithelial-mesenchymal transition and apoptosis in uterine carcinosarcoma. Mol Cancer (2017) 0.75
The Netrin-4/ Neogenin-1 axis promotes neuroblastoma cell survival and migration. Oncotarget (2016) 0.75
Genome-wide DNA methylation analysis identifies MEGF10 as a novel epigenetically repressed candidate tumor suppressor gene in neuroblastoma. Mol Carcinog (2016) 0.75
Neuronal leucine-rich repeat 1 negatively regulates anaplastic lymphoma kinase in neuroblastoma. Sci Rep (2016) 0.75
Bone marrow minimal residual disease was an early response marker and a consistent independent predictor of survival after anti-GD2 immunotherapy. J Clin Oncol (2015) 0.75
Regulation of myeloid cells by activated T cells determines the efficacy of PD-1 blockade. Oncoimmunology (2016) 0.75
Novel Src/Abl tyrosine kinase inhibitor bosutinib suppresses neuroblastoma growth via inhibiting Src/Abl signaling. Oncotarget (2016) 0.75
Transcriptional Profiling Reveals a Common Metabolic Program in High-Risk Human Neuroblastoma and Mouse Neuroblastoma Sphere-Forming Cells. Cell Rep (2016) 0.75
Hyperactivation of Alk induces neonatal lethality in knock-in AlkF1178L mice. Oncotarget (2014) 0.75
Characterization of pancreatic glucagon-producing tumors and pituitary gland tumors in transgenic mice overexpressing MYCN in hGFAP-positive cells. Oncotarget (2016) 0.75
High-throughput screening for chemical modulators of post-transcriptionally regulated genes. J Vis Exp (2015) 0.75
Neuroblastoma, a Paradigm for Big Data Science in Pediatric Oncology. Int J Mol Sci (2016) 0.75
Combination of Id2 Knockdown Whole Tumor Cells and Checkpoint Blockade: A Potent Vaccine Strategy in a Mouse Neuroblastoma Model. PLoS One (2015) 0.75
Chimeric antigen receptors and bispecific antibodies to retarget T cells in pediatric oncology. Pediatr Blood Cancer (2015) 0.75
Orbital Metastasis Is Associated With Decreased Survival in Stage M Neuroblastoma. Pediatr Blood Cancer (2015) 0.75
FX11 inhibits aerobic glycolysis and growth of neuroblastoma cells. Surgery (2016) 0.75
Sendai virus-mediated expression of reprogramming factors promotes plasticity of human neuroblastoma cells. Cancer Sci (2015) 0.75
The CXCR4/CXCR7/CXCL12 Axis Is Involved in a Secondary but Complex Control of Neuroblastoma Metastatic Cell Homing. PLoS One (2015) 0.75
Hallmarks of cancer: the next generation. Cell (2011) 140.01
The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer (2012) 24.94
Massive genomic rearrangement acquired in a single catastrophic event during cancer development. Cell (2011) 16.72
Cancer immunotherapy comes of age. Nature (2011) 12.35
Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma. Nat Med (2008) 11.49
Neuroblastoma: biological insights into a clinical enigma. Nat Rev Cancer (2003) 10.88
Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J Clin Oncol (1993) 10.87
Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage. Science (1984) 9.64
Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm. Nat Immunol (2010) 9.59
Humanized mice in translational biomedical research. Nat Rev Immunol (2007) 8.83
Recent advances in neuroblastoma. N Engl J Med (2010) 7.86
Identification of ALK as a major familial neuroblastoma predisposition gene. Nature (2008) 7.38
The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research. Clin Cancer Res (2009) 6.83
Intra-tumour heterogeneity: a looking glass for cancer? Nat Rev Cancer (2012) 6.82
Activating mutations in ALK provide a therapeutic target in neuroblastoma. Nature (2008) 6.80
The International Neuroblastoma Risk Group (INRG) classification system: an INRG Task Force report. J Clin Oncol (2008) 6.66
The International Neuroblastoma Pathology Classification (the Shimada system). Cancer (1999) 6.42
Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma. N Engl J Med (2010) 6.34
Oncogenic mutations of ALK kinase in neuroblastoma. Nature (2008) 5.80
Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma. Nature (2008) 5.32
Epitope landscape in breast and colorectal cancer. Cancer Res (2008) 5.29
Antibody therapy of cancer. Nat Rev Cancer (2012) 5.17
Long-term results for children with high-risk neuroblastoma treated on a randomized trial of myeloablative therapy followed by 13-cis-retinoic acid: a children's oncology group study. J Clin Oncol (2009) 5.12
A novel retinoblastoma therapy from genomic and epigenetic analyses. Nature (2012) 5.02
Targeted expression of MYCN causes neuroblastoma in transgenic mice. EMBO J (1997) 4.99
Chromosome 1p and 11q deletions and outcome in neuroblastoma. N Engl J Med (2005) 4.92
The genetic landscape of high-risk neuroblastoma. Nat Genet (2013) 4.71
Sequencing of neuroblastoma identifies chromothripsis and defects in neuritogenesis genes. Nature (2012) 4.53
Adoptive transfer of chimeric antigen receptor re-directed cytolytic T lymphocyte clones in patients with neuroblastoma. Mol Ther (2007) 4.07
Chromosome 6p22 locus associated with clinically aggressive neuroblastoma. N Engl J Med (2008) 3.80
Correlating telomerase activity levels with human neuroblastoma outcomes. Nat Med (1995) 3.74
Targeting natural killer cells and natural killer T cells in cancer. Nat Rev Immunol (2012) 3.43
Integrated genomic analyses identify ARID1A and ARID1B alterations in the childhood cancer neuroblastoma. Nat Genet (2012) 3.38
Single-agent interleukin-2 in the treatment of metastatic melanoma: a systematic review. Cancer Treat Rev (2007) 3.15
A subpopulation of Mac-1 (CD11b/CD18) molecules mediates neutrophil adhesion to ICAM-1 and fibrinogen. J Cell Biol (1993) 3.14
Targeting MYCN in neuroblastoma by BET bromodomain inhibition. Cancer Discov (2013) 3.11
Gain of chromosome arm 17q and adverse outcome in patients with neuroblastoma. N Engl J Med (1999) 3.03
Unlicensed NK cells target neuroblastoma following anti-GD2 antibody treatment. J Clin Invest (2012) 3.00
Mutation and cancer: neuroblastoma and pheochromocytoma. Am J Hum Genet (1972) 2.99
Molecular characterization of ALK, a receptor tyrosine kinase expressed specifically in the nervous system. Oncogene (1997) 2.80
Prognostic significance of gene expression profiles of metastatic neuroblastomas lacking MYCN gene amplification. J Natl Cancer Inst (2006) 2.79
High-dose rapid and standard induction chemotherapy for patients aged over 1 year with stage 4 neuroblastoma: a randomised trial. Lancet Oncol (2008) 2.72
Murine anti-GD2 monoclonal antibody 3F8 combined with granulocyte-macrophage colony-stimulating factor and 13-cis-retinoic acid in high-risk patients with stage 4 neuroblastoma in first remission. J Clin Oncol (2012) 2.70
Allelic loss of chromosome 1p as a predictor of unfavorable outcome in patients with neuroblastoma. N Engl J Med (1996) 2.66
Cytotoxicity of activated natural killer cells against pediatric solid tumors. Clin Cancer Res (2010) 2.51
Association of age at diagnosis and genetic mutations in patients with neuroblastoma. JAMA (2012) 2.49
Common variations in BARD1 influence susceptibility to high-risk neuroblastoma. Nat Genet (2009) 2.47
Catecholamine metabolism: a contemporary view with implications for physiology and medicine. Pharmacol Rev (2004) 2.42
Integrative genomics identifies LMO1 as a neuroblastoma oncogene. Nature (2010) 2.21
Membrane-bound IL-21 promotes sustained ex vivo proliferation of human natural killer cells. PLoS One (2012) 2.09
Cellular DNA content as a predictor of response to chemotherapy in infants with unresectable neuroblastoma. N Engl J Med (1984) 2.09
Detection of ganglioside GD2 in tumor tissues and sera of neuroblastoma patients. Cancer Res (1984) 2.01
Safety and immunologic effects of IL-15 administration in nonhuman primates. Blood (2009) 2.00
Germline mutations of the paired-like homeobox 2B (PHOX2B) gene in neuroblastoma. Am J Hum Genet (2004) 1.98
Retinoic acid-induced growth inhibition and morphologic differentiation of human neuroblastoma cells in vitro. J Natl Cancer Inst (1982) 1.96
LIN28B induces neuroblastoma and enhances MYCN levels via let-7 suppression. Nat Genet (2012) 1.96
Identification of 4Ig-B7-H3 as a neuroblastoma-associated molecule that exerts a protective role from an NK cell-mediated lysis. Proc Natl Acad Sci U S A (2004) 1.95
Therapeutic intervention with complement and beta-glucan in cancer. Immunopharmacology (1999) 1.94
Paracrine signaling through MYCN enhances tumor-vascular interactions in neuroblastoma. Sci Transl Med (2012) 1.89
Unequivocal delineation of clinicogenetic subgroups and development of a new model for improved outcome prediction in neuroblastoma. J Clin Oncol (2005) 1.82
The ALK(F1174L) mutation potentiates the oncogenic activity of MYCN in neuroblastoma. Cancer Cell (2012) 1.81
Oncogene mutation profiling of pediatric solid tumors reveals significant subsets of embryonal rhabdomyosarcoma and neuroblastoma with mutated genes in growth signaling pathways. Clin Cancer Res (2011) 1.80
Vesicular neurotransmitter transporters: from bacteria to humans. Physiol Rev (1995) 1.78
Valpha24-invariant NKT cells mediate antitumor activity via killing of tumor-associated macrophages. J Clin Invest (2009) 1.78
An integrated in vitro and in vivo high-throughput screen identifies treatment leads for ependymoma. Cancer Cell (2011) 1.78
MicroRNA miR-29 modulates expression of immunoinhibitory molecule B7-H3: potential implications for immune based therapy of human solid tumors. Cancer Res (2009) 1.74
Common variation at 6q16 within HACE1 and LIN28B influences susceptibility to neuroblastoma. Nat Genet (2012) 1.74
Credentialing preclinical pediatric xenograft models using gene expression and tissue microarray analysis. Cancer Res (2007) 1.71
Expression of the gene for multidrug-resistance-associated protein and outcome in patients with neuroblastoma. N Engl J Med (1996) 1.70
Activated ALK collaborates with MYCN in neuroblastoma pathogenesis. Cancer Cell (2012) 1.66
Germline PHOX2B mutation in hereditary neuroblastoma. Am J Hum Genet (2004) 1.66
Interleukin-15 biology and its therapeutic implications in cancer. Trends Pharmacol Sci (2011) 1.64
Phenotype restricted genome-wide association study using a gene-centric approach identifies three low-risk neuroblastoma susceptibility Loci. PLoS Genet (2011) 1.57
Antitumor activity of hu14.18-IL2 in patients with relapsed/refractory neuroblastoma: a Children's Oncology Group (COG) phase II study. J Clin Oncol (2010) 1.57
Downregulation and/or release of NKG2D ligands as immune evasion strategy of human neuroblastoma. Neoplasia (2004) 1.56
Trk receptor expression and inhibition in neuroblastomas. Clin Cancer Res (2009) 1.55
Neuroblastoma-derived gangliosides inhibit dendritic cell generation and function. Cancer Res (2001) 1.51
Genotypes of NK cell KIR receptors, their ligands, and Fcγ receptors in the response of neuroblastoma patients to Hu14.18-IL2 immunotherapy. Cancer Res (2010) 1.51
KIR and HLA genotypes are associated with disease progression and survival following autologous hematopoietic stem cell transplantation for high-risk neuroblastoma. Clin Cancer Res (2009) 1.50
Cyclin D1 and CDK4 activity contribute to the undifferentiated phenotype in neuroblastoma. Cancer Res (2008) 1.50
Promising therapeutic targets in neuroblastoma. Clin Cancer Res (2012) 1.48
Enhanced activity of hu14.18-IL2 immunocytokine against murine NXS2 neuroblastoma when combined with interleukin 2 therapy. Clin Cancer Res (2004) 1.46
Insulin-like growth factor I expression by tumors of neuroectodermal origin with the t(11;22) chromosomal translocation. A potential autocrine growth factor. J Clin Invest (1990) 1.44
An integrative genomics screen uncovers ncRNA T-UCR functions in neuroblastoma tumours. Oncogene (2010) 1.43
Natural killer T cells infiltrate neuroblastomas expressing the chemokine CCL2. J Exp Med (2004) 1.43
Targeting ALK in neuroblastoma--preclinical and clinical advancements. Nat Rev Clin Oncol (2012) 1.42
Decay-accelerating factor protects human tumor cells from complement-mediated cytotoxicity in vitro. J Clin Invest (1988) 1.41
Enhanced tumor trafficking of GD2 chimeric antigen receptor T cells by expression of the chemokine receptor CCR2b. J Immunother (2010) 1.38
Clinical significance of tumor-associated inflammatory cells in metastatic neuroblastoma. J Clin Oncol (2012) 1.37
Accumulation of segmental alterations determines progression in neuroblastoma. J Clin Oncol (2010) 1.36
Quiescence and γH2AX in neuroblastoma are regulated by ouabain/Na,K-ATPase. Br J Cancer (2012) 1.35
ALK receptor tyrosine kinase promotes cell growth and neurite outgrowth. J Cell Sci (2004) 1.34
Effect of bortezomib on human neuroblastoma cell growth, apoptosis, and angiogenesis. J Natl Cancer Inst (2006) 1.32
FCGR2A polymorphism is correlated with clinical outcome after immunotherapy of neuroblastoma with anti-GD2 antibody and granulocyte macrophage colony-stimulating factor. J Clin Oncol (2006) 1.32
Telomeres and telomerase: the means to the end (Nobel lecture). Angew Chem Int Ed Engl (2010) 1.31
Efficacy and pharmacokinetic/pharmacodynamic evaluation of the Aurora kinase A inhibitor MLN8237 against preclinical models of pediatric cancer. Cancer Chemother Pharmacol (2011) 1.30
Prevalence and functional consequence of PHOX2B mutations in neuroblastoma. Oncogene (2007) 1.30
Anti-GD2 antibody therapy for GD2-expressing tumors. Curr Cancer Drug Targets (2010) 1.28
Targeted expression of mutated ALK induces neuroblastoma in transgenic mice. Sci Transl Med (2012) 1.28
Evidence for a hereditary neuroblastoma predisposition locus at chromosome 16p12-13. Cancer Res (2002) 1.26
Somatic histone H3 alterations in pediatric diffuse intrinsic pontine gliomas and non-brainstem glioblastomas. Nat Genet (2012) 7.61
A novel retinoblastoma therapy from genomic and epigenetic analyses. Nature (2012) 5.02
Inactivation of the p53 pathway in retinoblastoma. Nature (2006) 4.57
Discovery of an oncogenic activity in p27Kip1 that causes stem cell expansion and a multiple tumor phenotype. Genes Dev (2007) 3.00
MDMX: from bench to bedside. J Cell Sci (2007) 2.78
Murine anti-GD2 monoclonal antibody 3F8 combined with granulocyte-macrophage colony-stimulating factor and 13-cis-retinoic acid in high-risk patients with stage 4 neuroblastoma in first remission. J Clin Oncol (2012) 2.70
Differentiated horizontal interneurons clonally expand to form metastatic retinoblastoma in mice. Cell (2007) 2.61
Association of age at diagnosis and genetic mutations in patients with neuroblastoma. JAMA (2012) 2.49
Rb regulates proliferation and rod photoreceptor development in the mouse retina. Nat Genet (2004) 1.94
Synthetic lethality between Rb, p53 and Dicer or miR-17-92 in retinal progenitors suppresses retinoblastoma formation. Nat Cell Biol (2012) 1.89
Identification and characterization of the first small molecule inhibitor of MDMX. J Biol Chem (2010) 1.85
The first knockout mouse model of retinoblastoma. Cell Cycle (2004) 1.74
Six3-mediated auto repression and eye development requires its interaction with members of the Groucho-related family of co-repressors. Development (2002) 1.73
Coexpression of normally incompatible developmental pathways in retinoblastoma genesis. Cancer Cell (2011) 1.67
The effects of transdermal nicotine on cognition in nonsmokers with schizophrenia and nonpsychiatric controls. Neuropsychopharmacology (2007) 1.67
Cells previously identified as retinal stem cells are pigmented ciliary epithelial cells. Proc Natl Acad Sci U S A (2009) 1.55
Compensation by tumor suppressor genes during retinal development in mice and humans. BMC Biol (2006) 1.54
Preparation and square wave electroporation of retinal explant cultures. Nat Protoc (2006) 1.48
Topotecan combination chemotherapy in two new rodent models of retinoblastoma. Clin Cancer Res (2005) 1.37
Retinoblastoma: one world, one vision. Pediatrics (2008) 1.29
Targeting the p53 pathway in retinoblastoma with subconjunctival Nutlin-3a. Cancer Res (2011) 1.21
Regulation of proliferation during central nervous system development. Semin Cell Dev Biol (2005) 1.11
Subconjunctival carboplatin and systemic topotecan treatment in preclinical models of retinoblastoma. Cancer (2010) 1.11
Neuronal differentiation and synaptogenesis in retinoblastoma. Cancer Res (2007) 1.10
Preclinical models for neuroblastoma: establishing a baseline for treatment. PLoS One (2011) 1.09
Retinoblastoma: from the two-hit hypothesis to targeted chemotherapy. Cancer Res (2007) 1.08
Analysis of MDM2 and MDM4 single nucleotide polymorphisms, mRNA splicing and protein expression in retinoblastoma. PLoS One (2012) 1.06
N-myc coordinates retinal growth with eye size during mouse development. Genes Dev (2008) 1.03
Changes in retinoblastoma cell adhesion associated with optic nerve invasion. Mol Cell Biol (2009) 1.02
Developmental defects in Rb-deficient retinae. Vision Res (2004) 1.02
Targeting MDM2 and MDMX in retinoblastoma. Curr Cancer Drug Targets (2007) 0.99
Mosaic deletion of Rb arrests rod differentiation and stimulates ectopic synaptogenesis in the mouse retina. J Comp Neurol (2006) 0.97
Mouse Mix gene is activated early during differentiation of ES and F9 stem cells and induces endoderm in frog embryos. Dev Dyn (2003) 0.97
RB1 gene inactivation by chromothripsis in human retinoblastoma. Oncotarget (2014) 0.96
An E2F binding-deficient Rb1 protein partially rescues developmental defects associated with Rb1 nullizygosity. Mol Cell Biol (2006) 0.96
AAV-mediated local delivery of interferon-beta for the treatment of retinoblastoma in preclinical models. Neuromolecular Med (2009) 0.95
Cross-species genomic and epigenomic landscape of retinoblastoma. Oncotarget (2013) 0.95
Whole-body physiologically based pharmacokinetic model for nutlin-3a in mice after intravenous and oral administration. Drug Metab Dispos (2010) 0.94
Genetics and epigenetics of human retinoblastoma. Annu Rev Pathol (2015) 0.92
Superselective intraophthalmic artery chemotherapy: what we do not know. Arch Ophthalmol (2011) 0.88
An Open Trial of Relapse Prevention Therapy for Smokers With Schizophrenia. J Dual Diagn (2013) 0.87
On the mechanism of action of SJ-172550 in inhibiting the interaction of MDM4 and p53. PLoS One (2012) 0.87
The role of whole brain radiation therapy in the management of melanoma brain metastases. Radiat Oncol (2014) 0.86
Glutamate regulates retinal progenitors cells proliferation during development. Eur J Neurosci (2006) 0.85
Expression of podocalyxin separates the hematopoietic and vascular potentials of mouse embryonic stem cell-derived mesoderm. Stem Cells (2014) 0.83
Statistical analysis of data from retroviral clonal experiments in the developing retina. Brain Res (2007) 0.82
Perspective: new genetic tools for studying retinal development and disease. Vis Neurosci (2005) 0.81
A new model of tumor susceptibility following tumor suppressor gene inactivation. Cell Cycle (2008) 0.81
Retinal progenitor cells, differentiation, and barriers to cell cycle reentry. Curr Top Dev Biol (2010) 0.80
The war on cancer: have we won the battle but lost the war? Oncotarget (2010) 0.79
Childhood cancer and developmental biology a crucial partnership. Curr Top Dev Biol (2011) 0.79
Automated tracing of horizontal neuron processes during retinal development. Neurochem Res (2011) 0.78
Retinoblastoma (Rb) regulates laminar dendritic arbor reorganization in retinal horizontal neurons. Proc Natl Acad Sci U S A (2011) 0.78
Genetically engineered mouse and orthotopic human tumor xenograft models of retinoblastoma. Methods Mol Biol (2015) 0.76
Pharmacokinetics and efficacy of the spleen tyrosine kinase inhibitor r406 after ocular delivery for retinoblastoma. Pharm Res (2014) 0.75
Oncogenesis and the development of treatments. Preface. Curr Top Dev Biol (2011) 0.75
In their own words: interviews with Cell Cycle. The first knockout mouse model of retinoblastoma. Cell Cycle (2009) 0.75